Countdown to Organon (OGN) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Organon (OGN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.
zacks.com
Read More
Organon (OGN) Ascends But Remains Behind Market: Some Facts to Note
In the most recent trading session, Organon (OGN) closed at $12.20, indicating a +0.66% shift from the previous trading day.
zacks.com
Read More
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
zacks.com
Read More
Analysts Estimate Organon (OGN) to Report a Decline in Earnings: What to Look Out for
Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zacks.com
Read More
Organon Appoints Ramona A. Sequeira to the Company's Board of Directors
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announces the appointment of Ramona A. Sequeira to the company's Board of Directors, effective July 1, 2025.
businesswire.com
Read More
Organon To Report First Quarter 2025 Results and Host Conference Call on May 1, 2025
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon will host Q1 2025 earnings results webcast and conference call on May 1, 2025.
businesswire.com
Read More
Organon (OGN) Laps the Stock Market: Here's Why
Organon (OGN) closed the most recent trading day at $11.30, moving +1.07% from the previous trading session.
zacks.com
Read More
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
zacks.com
Read More
Strength Seen in Organon (OGN): Can Its 8.5% Jump Turn into More Strength?
Organon (OGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
zacks.com
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
zacks.com
Read More
Why Organon (OGN) Could Beat Earnings Estimates Again
Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
zacks.com
Read More
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
zacks.com
Read More
Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S.
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announced it has acquired regulatory and commercial rights in the U.S. for TOFIDENCE™, a biosimilar to ACTEMRA®, for intravenous infusion.
businesswire.com
Read More
European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11
SHANGHAI, China & JERSEY CITY, N.J.--(BUSINESS WIRE)--Henlius and Organon announced the European Medicines Agency validates filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11.
businesswire.com
Read More
Organon (OGN) Falls More Steeply Than Broader Market: What Investors Need to Know
Organon (OGN) closed the most recent trading day at $14.56, moving -1.02% from the previous trading session.
zacks.com
Read More
Organon (OGN) Stock Declines While Market Improves: Some Information for Investors
In the closing of the recent trading day, Organon (OGN) stood at $15.39, denoting a -1.35% change from the preceding trading day.
zacks.com
Read More
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
zacks.com
Read More
Organon (OGN) Advances While Market Declines: Some Information for Investors
Organon (OGN) concluded the recent trading session at $15.70, signifying a +0.51% move from its prior day's close.
zacks.com
Read More
Why Organon Is A Top Pick For Income Investors
In mid-February, Organon pleasantly surprised me with its financial results for the fourth quarter of 2024. So, sales of Hadlima, a biosimilar to Humira, amounted to $44 million in the last three months of 2024, an increase of 83.3% year-on-year. Organon's dividend yield is 7.32%, which is significantly higher than that of the healthcare sector.
seekingalpha.com
Read More
New Analysis of Organon's VTAMA® (tapinarof) cream, 1% Phase 3 Data Shows Atopic Dermatitis Disease Activity Remained Low After Treatment-Free Interval in Adults and Children 2 Years of Age and Older
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a focus on women's health, today announced results from an analysis of the Phase 3 ADORING 3 open-label, long-term extension study evaluating VTAMA® (tapinarof) cream, 1% once daily in adults and children 2 years of age and older with atopic dermatitis (AD), also known as eczema. The findings demonstrate that AD disease activity remained mild in patients who had achieved treatment success and subsequently.
businesswire.com
Read More
High-Yield Healthcare: 3 Stocks With Strong Dividends
When it comes to dividend performers, healthcare usually takes a backseat to options like REITs and energy stocks. However, the sector's resilience, driven by aging populations and consistent demand for medical services, makes it an underrated source of steady income.
marketbeat.com
Read More
Organon & Co. (OGN) Q4 2024 Earnings Call Transcript
Organon & Co. (NYSE:OGN ) Q4 2024 Earnings Conference Call February 13, 2025 8:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO Juan Camilo Arjona Ferreira - Head of R&D Matt Walsh - CFO Conference Call Participants Terence Flynn - Morgan Stanley Michael Nedelcovych - TD Cowen Ethan Brown - JPMorgan David Amsellem - Piper Sandler Balaji Prasad - Barclays Jason Gerberry - Bank of America Umer Raffat - Evercore ISI Operator Thank you for standing by. My name is Celine and I will be your conference operator today.
seekingalpha.com
Read More
Organon (OGN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Organon (OGN) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
zacks.com
Read More
Organon (OGN) Q4 Earnings and Revenues Beat Estimates
Organon (OGN) came out with quarterly earnings of $0.90 per share, beating the Zacks Consensus Estimate of $0.86 per share. This compares to earnings of $0.88 per share a year ago.
zacks.com
Read More
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2024
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announces Q4 2024 and Full Year 2024 earnings results, ending December 31, 2024.
businesswire.com
Read More
Why Organon (OGN) Dipped More Than Broader Market Today
Organon (OGN) concluded the recent trading session at $14.62, signifying a -1.81% move from its prior day's close.
zacks.com
Read More
Organon (OGN) Rises Higher Than Market: Key Facts
The latest trading day saw Organon (OGN) settling at $15.97, representing a +0.82% change from its previous close.
zacks.com
Read More
Organon (OGN) Increases Despite Market Slip: Here's What You Need to Know
Organon (OGN) closed at $16.26 in the latest trading session, marking a +1.82% move from the prior day.
zacks.com
Read More
Organon To Report Fourth Quarter and Full Year 2024 Results and Host Conference Call on February 13, 2025
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon To Report Fourth Quarter and Full Year 2024 Results and Host Conference Call on February 13, 2025.
businesswire.com
Read More
Organon (OGN) Surpasses Market Returns: Some Facts Worth Knowing
Organon (OGN) closed the most recent trading day at $15.88, moving +0.89% from the previous trading session.
zacks.com
Read More
Organon: A Tricky 2025 Awaits, But I'm Happy With A >7% Dividend Yield
Organon has faced significant price volatility and underperformance since its spin-off from Merck, with shares down ~50% since 2021. Key products like Nexplanon and VTAMA are crucial for future growth, but uncertainties and competition pose significant risks to revenue projections. Organon's high debt and interest payments are significant concerns, despite low P/S and P/E ratios suggesting undervaluation, and a strong dividend yield.
seekingalpha.com
Read More
Organon & Co. (OGN) JPMorgan Annual Healthcare Conference - (Transcript)
Organon & Co. (NYSE:OGN ) JPMorgan Annual Healthcare Conference Call January 13, 2025 6:45 PM ET Company Participants Kevin Ali - Chief Executive Officer Matthew Walsh - Chief Financial Officer Conference Call Participants Chris Schott - JPMorgan Chris Schott Good afternoon, everybody. I'm Chris Schott from JPMorgan and it's my pleasure to be hosting this fireside chat with the Organon management team.
seekingalpha.com
Read More
Want $2,000 in Annual Dividends? Invest $11,000 in Each of These 3 Stocks.
Investing in dividend stocks can be an excellent way to boost your income each year. But the challenge can be generating a good return while keeping your risk low.
fool.com
Read More
Organon (OGN) Ascends While Market Falls: Some Facts to Note
Organon (OGN) closed at $15.06 in the latest trading session, marking a +0.74% move from the prior day.
zacks.com
Read More
Organon To Present at the 43rd Annual J.P. Morgan Healthcare Conference
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon CEO Kevin Ali and CFO Matthew Walsh to present in a fireside chat at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13th.
businesswire.com
Read More
Organon price target raised to $20 from $19 at Goldman Sachs
Goldman Sachs raised the firm's price target on Organon to $20 from $19 and keeps a Neutral rating on the shares. The firm cites the company's announced FDA approval of VTAMA for the topical treatment of atopic dermatitis, or AD, in adults and pediatric patients 2 years of age and older. VTAMA's AD approval addresses multiple unmet needs in the atopic dermatitis market previously demonstrated by their Phase 3 results, though the firm expects successful launch will require a heightened level of investment in sales/marketing support given the primary care dimensions of the AD market, the analyst tells investors in a research note.
https://thefly.com
Read More
Final Trades: Amazon, American Express and Organon
The CNBC 'Halftime Report' Investment Committee give their top stocks to watch for the second half.
youtube.com
Read More
Organon: 7% Yield, 4x P/E, Big Upside Potential
Organon is a deep value stock with a high 7.2% yield, supported by a diversified portfolio in women's health, biosimilars, and established pharmaceuticals. Despite stock price volatility, OGN has shown steady performance with growth in adjusted EBITDA and free cash flow. The acquisition of Dermavant and its promising treatment VTAMA for psoriasis and atopic dermatitis could be transformative, expanding OGN's reach into high-demand areas.
seekingalpha.com
Read More
Organon: Certainly A Risky Bet, But Looks Increasingly Compelling (Upgrade)
In this update, I'll focus on Organon's Q3 2024 results, earnings adjustments and segment performance, as well as the acquisition of Dermavant. Organon reported solid Q3 2024 results with 4% revenue growth, driven by strong volume growth more than offsetting pricing weakness and currency headwinds. The $1.2 billion Dermavant acquisition appears strategically acceptable but carries significant risks due to market competition and OGN's high debt.
seekingalpha.com
Read More
Organon & Co. (OGN) Q3 2024 Earnings Call Transcript
Organon & Co. (NYSE:OGN ) Q3 2024 Earnings Call Transcript October 31, 2024 8:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO Juan Camilo Arjona Ferreira - Head of R&D Matt Walsh - CFO Conference Call Participants Balaji Prasad - Barclays David Amsellem - Piper Sandler Jason Gerberry - Bank of America Umer Raffat - Evercore ISI Operator Thank you for standing by. My name is Mandeep and I'll be your operator today.
seekingalpha.com
Read More
Organon (OGN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Organon (OGN) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
zacks.com
Read More
Organon (OGN) Q3 Earnings and Revenues Beat Estimates
Organon (OGN) came out with quarterly earnings of $0.87 per share, beating the Zacks Consensus Estimate of $0.85 per share. This compares to earnings of $0.87 per share a year ago.
zacks.com
Read More
Organon Reports Results for the Third Quarter Ended September 30, 2024
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon Reports Q3 2024 Earnings.
businesswire.com
Read More
Ahead of Organon (OGN) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Evaluate the expected performance of Organon (OGN) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
zacks.com
Read More
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon expands dermatology capabilities through completion of Dermavant acquisition, including nonbiologic, non-steroidal VTAMA Cream, 1%.
businesswire.com
Read More
Earnings Preview: Organon (OGN) Q3 Earnings Expected to Decline
Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zacks.com
Read More
Want $300 in Dividends Every Month? Invest $20,000 in Each of These 3 Stocks
These dividend stocks all pay yields of around 6% and higher.
fool.com
Read More
5 Stocks to Buy for a Harris Presidency
The race for the White House is heating up and these five stocks are set to benefit if Kamala Harris claims victory.
kiplinger.com
Read More
Here's Why Organon (OGN) Gained But Lagged the Market Today
In the closing of the recent trading day, Organon (OGN) stood at $18.10, denoting a +0.56% change from the preceding trading day.
zacks.com
Read More
Organon (OGN) Loses -9.91% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Organon (OGN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
zacks.com
Read More
Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a focus on women's health, will release its third quarter 2024 financial results on October 31, 2024, prior to the company's webcast and conference call scheduled for 8:30 a.m. EDT. IPR&D and Milestones Organon currently expects that it will record $51 million of milestone expense in the third quarter of 2024, representing an impact of approximately $0.16 to both GAAP and non-GAAP earnings per share. O.
businesswire.com
Read More
Organon (OGN) Stock Falls Amid Market Uptick: What Investors Need to Know
Organon (OGN) closed at $18.10 in the latest trading session, marking a -0.11% move from the prior day.
zacks.com
Read More
Organon (OGN) Stock Dips While Market Gains: Key Facts
Organon (OGN) concluded the recent trading session at $18.58, signifying a -1.33% move from its prior day's close.
zacks.com
Read More
Final Trades: Organon, Howmet and the PSQ
The Investment Committee give you their top stocks to watch for the second half.
youtube.com
Read More
Why Organon (OGN) Outpaced the Stock Market Today
Organon (OGN) reachead $19.17 at the closing of the latest trading day, reflecting a +0.74% change compared to its last close.
zacks.com
Read More
Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B
Organon & Co OGN has agreed to acquire Roivant Sciences Ltd's ROIV Dermavant Sciences Ltd, which is focused on developing and commercializing therapeutics in immunodermatology.
benzinga.com
Read More
Roivant Flips a Skin Drug to Organon
Selling plaque psoriasis drug Vtama to Organon looks like another win for Roivant, which has been buying overlooked drugs, and then selling them for big returns.
barrons.com
Read More
Organon to buy therapy developer Dermavant for up to $1.2 billion
Healthcare company Organon said on Wednesday it has agreed to acquire Dermavant, a Roivant company, for up to $1.2 billion.
reuters.com
Read More
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon enters agreement to acquire Dermavant including innovative VTAMA (tapinarof) cream, 1%, a novel, non-steroidal topical dermatologic therapy.
businesswire.com
Read More
Organon (OGN) Outperforms Broader Market: What You Need to Know
Organon (OGN) concluded the recent trading session at $20.47, signifying a +0.89% move from its prior day's close.
zacks.com
Read More
JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability
JP Morgan notes that while there's a resurgence of interest and excitement in new product launches within the specialty group, including branded and complex generics/biosimilars, investors should be discerning about these opportunities.
benzinga.com
Read More
Is Trending Stock Organon & Co. (OGN) a Buy Now?
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
zacks.com
Read More
Is Most-Watched Stock Organon & Co. (OGN) Worth Betting on Now?
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
zacks.com
Read More
Organon (OGN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Organon (OGN) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
zacks.com
Read More
Organon (OGN) Surpasses Q2 Earnings Estimates
Organon (OGN) came out with quarterly earnings of $1.12 per share, beating the Zacks Consensus Estimate of $1.06 per share. This compares to earnings of $1.31 per share a year ago.
zacks.com
Read More
Top 4 stocks that could thrive if Kamala Harris wins the 2024 US election
As the 2024 US presidential election approaches, speculation about Kamala Harris potentially stepping into the Oval Office remains strong. Despite Donald Trump's assertion that Harris would be an easier opponent than Joe Biden, recent developments suggest Harris's presidency is a viable scenario.
invezz.com
Read More
Product Demand Likely to Aid Organon's (OGN) Q2 Earnings
Continued solid uptake of Organon's (OGN) products is expected to have driven second-quarter revenues.
zacks.com
Read More
Seeking Clues to Organon (OGN) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Organon (OGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2024.
zacks.com
Read More
Earnings Preview: Organon (OGN) Q2 Earnings Expected to Decline
Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zacks.com
Read More
Organon: Upcoming Q2 Earnings Can Sustain Upward Momentum
Organon stock experienced significant downside pressure in 2023, however positive Q423 and Q124 earnings have led to a bull run. Organon's business includes women's health, biosimilars, and established brands divisions. The company was spun out of Merck & Co in 2020, and saddled with >$8bn debt. I anticipate Organon's upcoming Q2 2024 earnings will underline growth potential, with a focus on global sales, new product performance, and solid debt management.
seekingalpha.com
Read More
3 Medical Services Industry Stocks to Buy as Healthcare Wage Increases
The Zacks Medical - Services industry is growing on nursing care market growth and digital healthcare adoption. ICLR, OGN and DOCS are set to gain the most.
zacks.com
Read More
Organon (OGN) Upgraded to Strong Buy: What Does It Mean for the Stock?
Organon (OGN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com
Read More
20 value stocks with high dividend yields and expected room to raise payouts
Last week's action in the stock market might have signaled a long-awaited shift away from a focus on Big Tech in the stock market to overlooked pockets of value.
marketwatch.com
Read More
Organon (OGN) Increases Yet Falls Behind Market: What Investors Need to Know
In the closing of the recent trading day, Organon (OGN) stood at $20.81, denoting a +0.39% change from the preceding trading day.
zacks.com
Read More
Organon (OGN) Stock Drops Despite Market Gains: Important Facts to Note
In the most recent trading session, Organon (OGN) closed at $19.93, indicating a -1.04% shift from the previous trading day.
zacks.com
Read More
Organon To Report Second Quarter 2024 Results and Host Conference Call on August 6, 2024
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon will report Q2 2024 results and host conference call on August 6, 2024. Organon estimates $15M milestone expenses in second quarter.
businesswire.com
Read More
Organon (OGN) Stock Sinks As Market Gains: Here's Why
In the most recent trading session, Organon (OGN) closed at $20.63, indicating a -0.77% shift from the previous trading day.
zacks.com
Read More
Value Investing Is Back! 3 Stocks With Strong Fundamentals to Buy Now
Volatility has increased on Wall Street while tech stocks are taking a breather. As a result, many investors are eyeing value stocks to buy, which may hold considerable potential for future returns.
investorplace.com
Read More
3 Stocks With Mouthwatering Dividends You Can Buy Right Now
Gilead Sciences is a safe, reliable dividend stock. Organon pays a high dividend yield and has been a big winner for investors this year.
fool.com
Read More
Organon (OGN) Just Overtook the 20-Day Moving Average
From a technical perspective, Organon (OGN) is looking like an interesting pick, as it just reached a key level of support. OGN recently overtook the 20-day moving average, and this suggests a short-term bullish trend.
zacks.com
Read More
CUPE 37 Members Reject City of Calgary Wage Package
CALGARY, Alberta--(BUSINESS WIRE)--Matt Sjogren, President of CUPE 37 (City of Calgary outside workers) issued the following statement after employees rejected a contract settlement offer. Last night, the members of CUPE 37 rejected a memorandum of settlement of 9% wage increases over a three-year period. This vote sends a strong and clear message to the City of Calgary about the severe impact of inflation on our members. City employees are facing unprecedented financial challenges. Many are st.
businesswire.com
Read More
European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14
SHANGHAI, China & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $OGN #denosumabbiosimilar--European Medicines Agency validates Organon and Henlius marketing authorization filings for Prolia and Xgeva (denosumab) biosimilar candidate HLX14.
businesswire.com
Read More
5 Relative Price Strength Stocks With Strong Return Potential
VITL, SFM, RCL, AEM and OGN are five stocks with explosive relative price strength.
zacks.com
Read More
Natixis Advisors L.P. Has $396,000 Stake in Organon & Co. (NYSE:OGN)
Natixis Advisors L.P. reduced its stake in shares of Organon & Co. (NYSE:OGN – Free Report) by 4.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,495 shares of the company’s stock after selling 1,285 shares during the quarter. Natixis Advisors L.P.’s holdings in Organon & Co. were worth $396,000 as of its most recent SEC filing. A number of other hedge funds and other institutional investors also recently made changes to their positions in OGN. Lindbrook Capital LLC increased its position in shares of Organon & Co. by 348.3% during the 4th quarter. Lindbrook Capital LLC now owns 1,838 shares of the company’s stock worth $27,000 after purchasing an additional 1,428 shares in the last quarter. Harvest Fund Management Co. Ltd increased its holdings in shares of Organon & Co. by 495.5% during the third quarter. Harvest Fund Management Co. Ltd now owns 1,602 shares of the company’s stock worth $28,000 after buying an additional 1,333 shares in the last quarter. Headlands Technologies LLC bought a new position in shares of Organon & Co. in the third quarter valued at approximately $35,000. GAMMA Investing LLC acquired a new position in shares of Organon & Co. in the 4th quarter worth approximately $38,000. Finally, EverSource Wealth Advisors LLC grew its position in Organon & Co. by 97.7% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 2,246 shares of the company’s stock worth $39,000 after acquiring an additional 1,110 shares during the last quarter. 77.43% of the stock is owned by institutional investors. Insiders Place Their Bets In other Organon & Co. news, insider Kirke Weaver bought 2,720 shares of Organon & Co. stock in a transaction dated Thursday, February 22nd. The shares were bought at an average price of $18.36 per share, with a total value of $49,939.20. Following the purchase, the insider now owns 15,181 shares of the company’s stock, valued at $278,723.16. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 1.17% of the company’s stock. Organon & Co. Stock Performance OGN stock opened at $21.80 on Monday. The company has a 50 day moving average price of $18.82 and a 200 day moving average price of $16.16. Organon & Co. has a fifty-two week low of $10.84 and a fifty-two week high of $24.08. The company has a debt-to-equity ratio of 181.35, a current ratio of 1.65 and a quick ratio of 1.15. The stock has a market capitalization of $5.61 billion, a PE ratio of 5.33, a price-to-earnings-growth ratio of 0.94 and a beta of 0.81. Organon & Co. (NYSE:OGN – Get Free Report) last released its earnings results on Thursday, February 15th. The company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of $0.73 by $0.14. Organon & Co. had a negative return on equity of 360.57% and a net margin of 16.50%. The company had revenue of $1.60 billion during the quarter, compared to the consensus estimate of $1.55 billion. Analysts forecast that Organon & Co. will post 4.3 EPS for the current year. Organon & Co. Announces Dividend The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 13th. Shareholders of record on Monday, May 13th will be issued a dividend of $0.28 per share. The ex-dividend date of this dividend is Friday, May 10th. This represents a $1.12 annualized dividend and a yield of 5.14%. Organon & Co.’s dividend payout ratio is currently 27.38%. Analyst Ratings Changes Several equities analysts have issued reports on OGN shares. The Goldman Sachs Group lifted their price objective on Organon & Co. from $18.00 to $20.00 and gave the company a “neutral” rating in a research report on Friday, May 3rd. Piper Sandler lifted their price target on Organon & Co. from $22.00 to $24.00 and gave the company an “overweight” rating in a report on Monday, April 29th. Get Our Latest Stock Report on Organon & Co. About Organon & Co. (Free Report) Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.
https://www.defenseworld.net
Read More